$REGN news
The latest REGN stock news: headlines, filings, AI summaries and sentiment for $REGN, updated around the clock.
- CytomX Therapeutics Reports Q3 2026 Financial Results and Varseta-M Clinical Updates
- Pomerantz Law Firm Investigates EyePoint, Inc. Following Clinical Trial Failures
- Sanofi Reports Strong Q3 2026 Results Driven by Dupixent and Upgraded Full-Year Guidance
- Regeneron Reports 36% Year-Over-Year Revenue Growth in Q3 2026
- Regeneron Forecasts Mid-Teens R&D Expense Growth for 2027 and $1B Sanofi Payment in Q4
- Regeneron Pharmaceuticals Shares Reach 52-Week High Following Strong Q3 Results
- Midday Market Update: Semiconductor and AI Stocks Slump Amid Mixed Earnings Reports
- Regeneron Reports Strong Q3 2026 Results Driven by Sanofi Collaboration and Libtayo Growth
- Regeneron Pharmaceuticals Shares Rise Following Q3 Revenue Beat
- REGENERON PHARMACEUTICALS, INC. - 10-Q Filing
- REGENERON PHARMACEUTICALS, INC. - 8-K Filing
- Regeneron Pharmaceuticals Reports Q3 Earnings Beat with $5.1 Billion in Revenue
- Major Energy and Pharmaceutical Earnings Scheduled for Friday Pre-Market
- Pomerantz Law Firm Investigates EyePoint, Inc. Following Clinical Trial Failures
- Kiniksa Pharmaceuticals Shares Surge Following Strong Q3 Results and Raised Full-Year Guidance
- EyePoint Pharmaceuticals' Stock Drops Over 80% After Late-Stage Trial Failure
- Regeneron's Future May Depend on Dupixent Amid Eylea Sales Decline
- UBS Resumes Buy Rating on Regeneron Amid Undervaluation of Dupixent Potential
- Regeneron Announces Earnings Impact from Expanded Collaboration with Sanofi
- REGENERON PHARMACEUTICALS, INC. - 8-K Filing
- Regeneron Reports Mixed Results in Ovarian Cancer Therapy Trial
- Sanofi Agrees to Pay Up to $8 Billion for Expanded Long-Acting Drug Pipeline
- Regeneron and Novo Nordisk Combination Therapy Reduces Muscle Loss in Study
- REGENERON PHARMACEUTICALS, INC. - 8-K Filing
- Citi Downgrades Moderna to Sell Amid Concerns Over Stock Valuation
- Investor Alert: Pomerantz Law Firm Investigates EyePoint, Inc.
- Regeneron Reports Strong Performance from EYLEA HD, Dupixent Growth, and Upcoming Pipeline Catalysts
- AstraZeneca's Tozorakimab Shows Strong Results in COPD Trials
- AbbVie Reports Strong Phase 3 Results for Myeloma Treatment Etentamig
- North Immunology to go public via reverse merger with Aethlon Medical
- Investor Alert: Pomerantz Law Firm Investigates EyePoint, Inc.
- AstraZeneca's COPD Drug Shows Strong Trial Results and Blockbuster Potential
- Investor Alert: Pomerantz Law Firm Investigates EyePoint, Inc.
- FDA Approves Regeneron's Rare-Disease Drug Pasatru Despite Small Market Potential
- Veeva Systems Reports Strong Q2 Earnings and Raises Full-Year Guidance
- July Healthcare Sector Performance: Regeneron and DexCom Outshine Peers
- Sanofi Aims to Rebuild Trust with Regeneron; Apnimed's Upsized IPO Adds Momentum
- Regeneron Pharmaceuticals Reports Strong Q2 Growth Driven by Dupixent, EYLEA HD
- Alnylam Pharma Reports Q2 2026 Earnings with Strong Revenue Growth
- Regeneron Reports Strong Q2 Earnings with Revenue Growth and Record Sales
- Regeneron Exceeds Q2 Earnings and Revenue Expectations Driven by Dupixent Growth
- Regeneron Exceeds Quarterly Estimates, Driven by Strong Sales of Eczema Drug Dupixent
- Regeneron Stock Rises on Strong Second-Quarter Results
- REGENERON PHARMACEUTICALS, INC. - 8-K Filing
- Regeneron Faces Securities Class Action Over Failed Melanoma Trial
- Class Action Lawsuit Filed Against Regeneron Pharmaceuticals Over Alleged Misleading Statements
- Merck Receives U.S. FDA Approval for Cholesterol Pill Lipfendra
- $47 Million Bankruptcy Payment Ordered for 23andMe Hack Victims
- Eli Lilly and Regeneron Join FDA Pilot Program to Enhance US Drug Manufacturing
- Eli Lilly and Regeneron Selected for FDA PreCheck Pilot Program to Accelerate Drug Manufacturing Facility Reviews